Eli Lilly releases Q3 2025 financial results: Tirzepatide posts strong growth, with sales in the first three quarters surpassing those of Keytruda.
Publish Time:
2025-11-18
Eli Lilly announced its Q3 2025 results, reporting a 54% year-over-year increase in revenue for the third quarter of 2025, reaching $17.6 billion—driven primarily by strong sales growth of tirzepatide. In Q3 2025, earnings per share (EPS), based on reported financial figures, rose by $5.14 to $6.21; meanwhile, adjusted EPS under Non-GAAP standards increased by $5.84 to $7.02. For the full year 2025, the company raised its revenue guidance to a range of $63.0 billion to $63.5 billion, while lifting its EPS outlook to $21.80–$22.50 per share. Under Non-GAAP adjustments, the EPS guidance was further revised upward to a range of $23.00–$23.70 per share.
From a therapeutic perspective, Eli Lilly is currently focusing on four major disease areas: cardiovascular metabolism, oncology, immunology, and neuroscience. Among these, the cardiovascular metabolism segment remains Eli Lilly's core business, accounting for 74.9% of total revenue. In Q3 2025, this segment generated $13.178 billion in revenue, representing a robust 78% year-over-year growth, primarily driven by the rapid expansion of tirzepatide sales. Meanwhile, the oncology segment posted revenue of $2.408 billion in Q3 2025, up 8% compared to the same period last year. The immunology segment delivered $1.362 billion in revenue during Q3 2025, reflecting a 15% increase from the previous year. Lastly, the neuroscience segment reported $316 million in revenue for Q3 2025, marking a 10% decline from the prior year.
Relevant Information
undefined
